Meningococcal Conjugate Vaccine Market Size, Share & Trend Analysis; By Composition (Mono and Combination Vaccines); By Brand (Menveo, Menactra, Nimenrix, and NeisVac-C); By End User (Children, Preteens or Teens, and Adults), Regional Stance, Competitive Tactics, and Segment Forecast to 2030

Meningococcal Conjugate Vaccine Market at a Glance:

As per Reports and Insights Analysis, the meningococcal conjugate vaccine market is expected to grow at a CAGR of 6.5% during the forecast period of 2022 to 2030.

This market research report on the global market for meningococcal conjugate vaccine constructed by the Reports and Insights team intends to address market aspects such as key drivers, challenges, and opportunities for industry participants. Furthermore, it will encompass a regional outlook, market segmentation outlook, and market trends for the meningococcal conjugate vaccine. Market size and share, industry and product insights, SWOT analysis, Porter's five forces analysis, PESTEL analysis, heat map analysis, market prediction, and information on the key players active in the market of meningococcal conjugate vaccine.

Meningitis, a bacterial infection that can affect the spinal cord and brain and produce meningococcal illness, can be fatal or result in life-long, incapacitating medical issues.

When an infected individual coughs or sneeze, tiny droplets of saliva are released into the air and spread the meningococcal disease from one person to another. The majority of the time, the bacteria is spread by having close physical contact with an infected individual, particularly through kissing or sharing a drink, or eating utensils.

To stop infection brought on by serogroups A, C, W, and Y, the meningococcal conjugate vaccine is employed. Your body can build immunity to meningitis with the help of this vaccination, but it won't cure an existing infection that is still active.

This vaccination, sold under the brand name Menactra, is recommended for use in children and adults between the ages of 9 months and 55. Menveo is intended for use by toddlers and adults 2 months of age and older. For adults and kids who are at least 2 years old, there is MenQuadfi.

Download Free Sample Report

Scope of the Report:

Meningococcal Conjugate Vaccine Market Dynamics        

Market Drivers:

The prevalence of diseases brought on by microbes like Neisseria meningitides is on the rise, as is healthcare infrastructure, the development of high-quality vaccines at competitive prices, and surging public awareness of meningococcal vaccination and related immunization. These are the main factors responsible for the increase in the meningococcal conjugate vaccine market.

Market Challenges:

However, prohibitive prices, unfavorable vaccination side effects, and onerous regulatory regulations restrain the expansion of the meningococcal conjugate vaccine industry worldwide. 

Market Opportunities:

The creation of combination vaccines and numerous merger and acquisition plans among major vendors are anticipated to fuel the market's expansion in the near term. For the market players, this will translate into attractive prospects.

Meningococcal Conjugate Vaccine Market Segmentation Outlook

• By Brand:

      Menactra

      Menveo

      NeisVac-C

      Nimenrix

      Others (Meningitec, menAfriVac, Menjugate, and NmVac4-DT)

• By Composition:

      Combination Vaccines

      Mono Vaccines

• By End User:

      Adults

      Children

      Preteens or Teens

• By Region:

Africa

Asia-Pacific 

Europe 

Latin America

Middle East

Meningococcal Conjugate Vaccine Market Regional Outlook

In terms of revenue, North America will continue to lead the global market in 2021, followed by Europe. The North American market is being fueled by favorable recommendations and assistance from governments as well as significant R&D expenditures. Additionally, it is projected that a strong healthcare system and an increase in awareness campaigns in the area will fuel market expansion. Market participants are also actively engaged in public education to drive to improve the region's uptake of the meningococcal vaccine. For instance, the ASK2BSure campaign from GlaxoSmithKline Plc. was launched in August 2021 to encourage parents to talk to their doctors about vaccinating their children against meningitis B.

During the projection period, it is anticipated that the Asia Pacific market would expand significantly. The demand for meningococcal vaccines in this area is escalating as a consequence of the increasing pediatric population and increased government efforts to combat the disease's rise in prevalence. Additionally, there are non-profit organizations in the area that offer information and raise public and professional awareness. Consequently, it is anticipated that meningococcal infection vaccination rates will rise.

To learn more about this report, request a free sample copy